Frontotemporal Dementia (FTD) Clinical Trials

6 recruitingLast updated: June 18, 2026

There are 6 actively recruiting frontotemporal dementia (ftd) clinical trials across 4 countries. Studies span Early Phase 1, Not Applicable, Phase 2. Top locations include Baltimore, Maryland, United States, Brescia, BS, Italy, Calgary, Alberta, Canada. Updated daily from ClinicalTrials.gov.


Frontotemporal Dementia (FTD) Trials at a Glance

6 actively recruiting trials for frontotemporal dementia (ftd) are listed on ClinicalTrialsFinder across 6 cities in 4 countries. The largest study group is Early Phase 1 with 1 trial, with the heaviest enrollment activity in Baltimore, Brescia, and Calgary. Lead sponsors running frontotemporal dementia (ftd) studies include AC Immune SA, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, and IRCCS Centro San Giovanni di Dio Fatebenefratelli.

Browse frontotemporal dementia (ftd) trials by phase

Treatments under study

About Frontotemporal Dementia (FTD) Clinical Trials

Looking for clinical trials for Frontotemporal Dementia (FTD)? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Frontotemporal Dementia (FTD) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Frontotemporal Dementia (FTD) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Not Applicable

Transcranial Alternating Current Stimulation in Frontotemporal Dementia

Frontotemporal Dementia (FTD)Transcranial Alternating Current Stimulation
IRCCS Centro San Giovanni di Dio Fatebenefratelli30 enrolled1 locationNCT07505784
Recruiting

Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches

FTDALS (Amyotrophic Lateral Sclerosis)Frontotemporal Dementia (FTD)+3 more
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta230 enrolled4 locationsNCT06856850
Recruiting
Phase 2

Vortioxetine for the Treatment of Mood and Cognitive Symptoms in Frontotemporal Dementia

fronto-temporal dementiaFrontotemporal DementiaFrontotemporal Degeneration+3 more
Johns Hopkins University50 enrolled1 locationNCT06604520
Recruiting

Comprehensive Assessment of Neurodegeneration and Dementia

DementiaMild Cognitive Impairment (MCI)Subjective Cognitive Impairment+7 more
McGill University1,573 enrolled19 locationsNCT03402919
Recruiting
Early Phase 1

[18F]ACI-19626 PET in TDP-43 Proteinopathies

Amyotrophic Lateral Sclerosis(ALS)Alzheimer's Disease(AD)Frontotemporal Dementia (FTD)+2 more
AC Immune SA45 enrolled1 locationNCT06891716
Recruiting

Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders

Parkinson DiseaseAmyotrophic Lateral Sclerosis(ALS)Alzheimer&Amp;#39;s Disease (AD)+1 more
Neuromed IRCCS110 enrolled1 locationNCT06803784